TwinBeech Capital’s Royalty Pharma RPRX Stock Holding History

TwinBeech Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$312K	Buy	+5,569	New	+$290K	0.06%	284
2026 Q1	–	Sell	-87,629	Closed	-$3.39M	–	788
2025 Q4	$3.39M	Buy	+87,629	New	+$3.34M	0.24%	125
2025 Q2	–	Sell	-163,798	Closed	-$5.1M	–	941
2025 Q1	$5.1M	Buy	+163,798	New	+$5.19M	0.09%	241
2024 Q4	–	Sell	-182,628	Closed	-$5.17M	–	886
2024 Q3	$5.17M	Buy	182,628 +71,919	+65%	+$1.99M	0.1%	240
2024 Q2	$2.92M	Buy	+110,709	New	+$3.07M	0.06%	286
2024 Q1	–	Sell	-567,250	Closed	-$15.9M	–	808
2023 Q4	$15.9M	Buy	567,250 +203,959	+56%	+$5.6M	0.26%	111
2023 Q3	$9.86M	Sell	363,291 -46,418	-11%	-$1.38M	0.19%	149
2023 Q2	$12.6M	Buy	+409,709	New	+$13.9M	0.25%	124
2023 Q1	–	Sell	-430,613	Closed	-$17M	–	851
2022 Q4	$17M	Buy	+430,613	New	+$18M	0.32%	86
2022 Q2	–	Sell	-178,798	Closed	-$6.97M	–	701
2022 Q1	$6.97M	Buy	178,798 +93,200	+109%	+$3.66M	0.31%	97
2021 Q4	$3.41M	Buy	+85,598	New	+$3.33M	0.19%	150
2021 Q3	–	Sell	-103,101	Closed	-$4.23M	–	730
2021 Q2	$4.23M	Buy	+103,101	New	+$4.39M	0.51%	60

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TwinBeech Capital's RPRX Position: Q2 2026 in Review

TwinBeech Capital opened a new position in Royalty Pharma (RPRX) in Q2 2026: 5,569 shares worth $312K. The stake represents 0.06% of the portfolio and ranks #284 among its holdings. This is a return to the name: TwinBeech Capital previously reported a position in RPRX as recently as Q4 2025.

TwinBeech Capital first reported a position in RPRX in Q2 2021 and has held it in 12 quarters since. The position peaked at $17M in Q4 2022. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

TwinBeech Capital held 5,569 shares of Royalty Pharma worth $312K as of Q2 2026.
Royalty Pharma was a new TwinBeech Capital position in Q2 2026.
Royalty Pharma made up 0.06% of TwinBeech Capital's portfolio in Q2 2026, its #284 holding.
TwinBeech Capital first reported a position in Royalty Pharma in Q2 2021 and has held it in 12 quarters since.
TwinBeech Capital's Royalty Pharma position peaked at $17M in Q4 2022.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.